Refractory Pityriasis Lichenoides in the Era of Targeted Therapy: A Practical Clinical Review

Pityriasis lichenoides (PL) encompasses pityriasis lichenoides chronica (PLC), pityriasis lichenoides et varioliformis acuta (PLEVA), and the rare, potentially life-threatening febrile ulceronecrotic Mucha–Habermann disease (FUMHD). Clinical overlap, an incompletely understood pathogenesis, and heterogeneous treatment outcomes complicate management. This narrative review distinguishes the clinical presentations, reviews the diagnostic contribution and limitations of dermoscopy and T-cell receptor clonality, and critically examines conventional and targeted treatments. Narrowband ultraviolet B phototherapy, oral antibiotics, and methotrexate remain conventional options supported mainly by observational evidence. Reports involving Janus kinase inhibitors, apremilast, dupilumab, and stapokibart are encouraging but uncontrolled; concomitant treatment, atopic comorbidity, incomplete prior treatment exposure, and patient refusal of conventional options limit interpretation. We propose explicitly non-validated definitions of treatment exposure, active disease, response, relapse, and refractoriness to improve clinical reporting. A practical algorithm provides an immediate emergency pathway for suspected FUMHD and separates conventional management from experimental rescue treatment. Molecular testing should be clinically indicated and interpreted within clinicopathological reassessment because clonality alone cannot distinguish PL from lymphomatoid papulosis or cutaneous lymphoma. Prospective studies with standardized outcomes, treatment-withdrawal data, and systematic safety monitoring are needed.

Authors

Institutions

Publication Details

Journal
Medicina
Published
2026-11-19
DOI
https://doi.org/10.3390/medicina62112272
Primary Topic
Cutaneous lymphoproliferative disorders research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Refractory Pityriasis Lichenoides in the Era of Targeted Therapy: A Practical Clinical Review

Maddalena Napolitano, Claudio Brescia, Chiara Palagiano
Medicina
Cutaneous lymphoproliferative disorders research
article

Refractory Pityriasis Lichenoides in the Era of Targeted Therapy: A Practical Clinical Review

Maddalena Napolitano, Claudio Brescia, Chiara Palagiano
article en

Abstract

Pityriasis lichenoides (PL) encompasses pityriasis lichenoides chronica (PLC), pityriasis lichenoides et varioliformis acuta (PLEVA), and the rare, potentially life-threatening febrile ulceronecrotic Mucha–Habermann disease (FUMHD). Clinical overlap, an incompletely understood pathogenesis, and heterogeneous treatment outcomes complicate management. This narrative review distinguishes the clinical presentations, reviews the diagnostic contribution and limitations of dermoscopy and T-cell receptor clonality, and critically examines conventional and targeted treatments. Narrowband ultraviolet B phototherapy, oral antibiotics, and methotrexate remain conventional options supported mainly by observational evidence. Reports involving Janus kinase inhibitors, apremilast, dupilumab, and stapokibart are encouraging but uncontrolled; concomitant treatment, atopic comorbidity, incomplete prior treatment exposure, and patient refusal of conventional options limit interpretation. We propose explicitly non-validated definitions of treatment exposure, active disease, response, relapse, and refractoriness to improve clinical reporting. A practical algorithm provides an immediate emergency pathway for suspected FUMHD and separates conventional management from experimental rescue treatment. Molecular testing should be clinically indicated and interpreted within clinicopathological reassessment because clonality alone cannot distinguish PL from lymphomatoid papulosis or cutaneous lymphoma. Prospective studies with standardized outcomes, treatment-withdrawal data, and systematic safety monitoring are needed.

MedicinaVol. 62(11)
Federico II University Hospital (IT), University of Naples Federico II (IT)
Cutaneous lymphoproliferative disorders research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon